UC Irvine

UC Irvine Previously Published Works

Title

Rate of FEV1 change following lung volume reduction surgery.

Permalink

<https://escholarship.org/uc/item/1770g8bz>

Journal

Chest, 113(3)

ISSN

0012-3692

Authors

Brenner, M
McKenna, RJ
Gelb, AF
[et al.](#)

Publication Date

1998-03-01

DOI

10.1378/chest.113.3.652

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Rate of FEV₁ Change Following Lung Volume Reduction Surgery*

Matthew Brenner, MD, FCCP; Robert J. McKenna, Jr., MD;
Arthur F. Gelb, MD, FCCP; Richard J. Fischel, MD; and Archie F. Wilson, MD

Introduction: Lung volume reduction surgery (LVRS) improves pulmonary function and dyspnea symptoms acutely in selected patients with heterogeneous emphysema. Limited data are available regarding long-term function following LVRS. We analyzed short-term (<6 months) and long-term rate of change of pulmonary function in 376 patients who underwent unilateral or bilateral LVRS using thoracoscopic or median sternotomy, staple, laser, or combined techniques. We hypothesized that the long-term rate of deterioration in lung function would be dependent on the surgical procedure used and would be greatest in those with the largest short-term postoperative improvement.

Methods: Pulmonary function was assessed preoperatively and at repeated intervals following LVRS. The change in pulmonary function over time was assessed for each patient by determining the individual change in FEV₁ using linear regression analysis short and long term. Overall rate of change in pulmonary function was calculated for the composite group of patients and subgrouped by operative procedure.

Results: Lung function appears to improve in the first few months following LVRS in most patients, maximizing at approximately 3 to 6 months and declining thereafter. The short-term incremental improvement following staple procedures is superior to improvements following laser procedures or unilateral surgery: FEV₁ increase (mean±SD) of 0.39±0.03 L for bilateral staple, 0.25±0.03 L for unilateral staple, 0.10±0.03 L for unilateral laser, and 0.22±0.1 L for mixed unilateral staple/laser procedures. However, the long-term rate of decline in FEV₁ was greatest for bilateral staple LVRS procedures as well: 0.255±0.057 L/yr for bilateral staple, 0.107±0.068 L/yr for unilateral staple, 0.074±0.034 L/yr for unilateral laser, and 0.209±0.12 L/yr for mixed staple laser procedures. There was a general correlation between the magnitude of short-term incremental improvement and the rate of deterioration in FEV₁ (r=0.292, p=0.003).

Conclusions: While bilateral staple LVRS procedures lead to greater short-term improvement in FEV₁, the more rapid rate of FEV₁ decline in these patients and the general association between greater short-term incremental improvement and higher rates of deterioration raise questions regarding optimal long-term procedures. Further studies will be needed to answer these important questions. (CHEST 1998; 113:652-59)

Key words: duration; FEV₁; lung volume reduction surgery

Abbreviation: LVRS=lung volume reduction surgery

Lung volume reduction surgery (LVRS) has been demonstrated to provide short-term palliative benefits in terms of pulmonary function and dyspnea

symptoms in selected patients with heterogeneous emphysema. Limited data are available regarding long-term benefits following LVRS. Understanding of long-term response to lung volume reduction is essential for assessing the overall value of LVRS procedures and their eventual role in management of emphysema.

A number of LVRS approaches have been described, including the following: unilateral, bilateral, thoracoscopic, median sternotomy, staple, and laser LVRS procedures. Acutely, bilateral staple LVRS appears to provide superior incremental benefit and equivalent or improved morbidity in comparison to other LVRS procedures and has gained favor as the

*From Divisions of Pulmonary Medicine and Beckman Laser Institute (Drs. Brenner and Wilson), UC Irvine Medical Center, and Chapman Lung Center (Drs. McKenna and Fischel), Orange, Calif; Lakewood Regional Medical Center (Dr. Gelb), Lakewood, Calif; and UCLA Medical Center (Drs. McKenna and Gelb), Los Angeles.

Supported in part by DOE grant DE-F603-91ER61227, ALA grant CI-030-N, CTRDRP No. 6RT-0158, and a Chapman Medical Center Research Grant.

Manuscript received February 10, 1997; revision accepted August 6.

Reprint requests: Matt Brenner, MD, FCCP, Pulmonary and Critical Care Medicine Division, UC Irvine Medical Center, 101 City Dr S, Orange, CA 92668

predominant LVRS procedure at most institutions.¹⁻¹¹ However, questions arise regarding possible discrepancies between short-term and long-term response. Is the rate of deterioration equivalent among the various surgical procedures? Is the rate of deterioration related to the initial incremental response? Is it possible that sequential unilateral procedures could, in the long run, provide superior palliation in certain subgroups compared with bilateral procedures? In addition to describing long-term postoperative outcomes, examination of these questions will aid in further understanding the optimal approaches to LVRS.

Our research group had the unique opportunity to compare response to these various approaches in a large series of patients treated by a single group of surgeons at Chapman Medical Center over a 3-year period.^{2,5} In this study, we analyze the short-term (<6 months) and long-term pulmonary function response as well as the rate of change of pulmonary function in 376 patients who underwent unilateral or bilateral LVRS thoracoscopic or median sternotomy, staple, laser, or combined LVRS techniques based on the initial type of procedure and the initial incremental response to treatment. We hypothesized that the long-term rate of deterioration in lung function would be dependent on the surgical procedure and would be greatest in those with the largest short-term postoperative improvement.

MATERIALS AND METHODS

All patients who underwent LVRS at Chapman Medical Center from May 1994 to July 1996 were included in this evaluation. Patients underwent baseline complete pulmonary function testing, including the following: spirometry, gas exchange measures (room air arterial blood gas measurement, diffusion of carbon monoxide), plethysmography, and gas dilution lung volumes (Table 1). Maximum inspiratory and expiratory flow volume curves and thoracic gas volume were measured in a plethysmograph (Collins/Cybermedic Classic TCI and Body Plethysmograph; Warren E. Collins Inc; Braintree, Mass), and compared with predicted values as previously described.^{2,5} All patients underwent LVRS at Chapman Medical Center by one or both of the two thoracic surgeons in the research group (R.J.M., R.J.F.); no procedures were performed at any other center in this protocol.

Repeated pulmonary function studies were requested from patients 3 months postoperatively, at 6 months, and at approximately 6-month intervals thereafter (Table 2). Whenever possible, repeated spirometry was performed at least once at Chapman Medical Center within 3 months of surgery, but subsequent spirometry data were obtained from the referring site.

Selection criteria and operative procedures for thoracoscopic LVRS have been described previously.^{2,5} Informed consent was obtained from all patients. Despite maximal medical management, all patients were markedly symptomatic. Chest radiographs showed hyperexpansion of the thorax with flattening or inversion of the diaphragms.

Contraindications to surgery included current cigarette smoking, age older than 80 years, severe cardiac disease (congestive heart failure, significant coronary or valvular disease), history of cancer within the last 5 years, ventilator dependency, or prior thoracic surgery. Relative contraindications included age older than 75 years, severe anxiety, severe depression, or CO₂ retention with resting PaCO₂ >55 mm Hg.^{2,5}

To be accepted for the procedure, the pattern of emphysema on CT had to be severe and heterogeneous. Radionuclide lung perfusion scans were also used to confirm the heterogeneous pattern of emphysema.^{2,5}

Thoracoscopic LVRS Operative Methods

Operative procedures for thoracoscopic laser and staple volume reduction surgery have been described previously as well.^{2,5} All patients underwent video-assisted thoracic surgery under paralyzed (pipecuronium) general anesthesia (isoflurane) using a left-sided double-lumen tube (Mallinckrodt Anesthesia; St. Louis).

All the procedures were performed with patients in the lateral decubitus position by one surgical group (R.J.M., R.J.F., M.B.). The trocar and thoracoscope were placed through the 10th intercostal space in the posterior axillary line. Three additional 1- to 2-cm incisions were made for standard instruments. Patients were turned to the contralateral decubitus position for separate sterile preparation and draping after completion of surgery on the initial side in patients undergoing bilateral thoracoscopic procedures.

Preoperative lung CT scans and ventilation perfusion scans were used to identify areas of dysfunctional or degenerated lung targeted for resection with the staples.^{2,5} Ring forceps manipulated the lung into a 60-mm endoscopic stapler (ELC 60; Ethicon; Cincinnati) with bovine pericardium (Peristrips; Biovascular; Saint Paul, Minn) or bovine collagen matrix (Instat; Johnson and Johnson; New Brunswick, NJ) to buttress the staples. The staples were fired an average of 15 times for bilateral operations. Typically, approximately half of the upper lobe was resected in patients with upper lobe disease.

For unilateral laser lung volume reduction procedures, an Nd-YAG laser was used in a contact mode; photocoagulation of emphysematous areas was achieved using 10 W and resulted in nearly complete visual contraction of the affected site.

Combined Staple/Laser LVRS Procedures

Combined staple/laser LVRS procedures were used in patients with focal areas of bullous disease >2 cm in diameter (though no patients were included in this series if bullae were >8 cm). Methods were identical to those described in the individual laser and staple procedures. Staple volume reduction was performed in the most involved regions. The remaining lung surface was then exposed to the contact tip Nd-YAG laser in the usual manner.⁵

Median Sternotomy Procedures

Bilateral staple LVRS was performed on a limited number of patients early in the program using a standard median sternotomy approach and bilateral bovine pericardium buttressed stapling using standard techniques.^{3,6} This approach was replaced by the bilateral thoracoscopic method once the bilateral thoracoscopic surgical techniques were developed.²

Response Assessment

To be included in the short-term follow-up evaluation analyses in this study, patients were required to have at least two follow-up

Table 1—Baseline Characteristics*

	All Patients (n=376)		Patients With Multiple F/U (n=180)		Patients Without F/U (n=45)		Patients With Single F/U (n=151)	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Age, yr	67.30	0.48	67.29	0.49	68.90	0.73	67.80	0.63
Height, in	67.70	0.25	67.67	0.25	67.70	0.52	67.80	0.30
Weight, lbs	149.90	2.20	149.86	2.20	146.36	0.40	147.90	2.57
Dyspnea score [†]	2.92	0.06	2.91	0.06	3.11	0.12	3.10	0.06
FVC, L	2.05	0.05	2.05	0.05	1.86	0.10	2.04	0.06
FEV ₁ , L	0.67	0.02	0.67	0.02	0.6 [‡]	0.03	0.67	0.02
DCO, mL/mm Hg/min	5.50	0.22	5.51	0.22	3.90	0.29	4.86	0.26
TLC, L	7.36	0.12	7.36	0.12	6.95	0.28	7.47	0.13
RV, L	4.65	0.09	4.62	0.10	4.50	0.23	4.73	0.12
RV/TLC	0.69	0.02	0.68	0.02	6.85	0.01	0.70	0.04
PCO ₂ , mm Hg	43.00	0.55	41.00	0.55	44.90	1.20	43.10	0.73
PO ₂ , mm Hg	64.80	0.88	64.00	0.89	57.49 [‡]	1.57	62.48	1.04
Hospital stay, d	9.18	0.52	9.81	0.52	11.96	1.24	9.72	0.74
Change in FEV ₁ , L	0.24	0.02	0.24	0.02				
% Change in FEV ₁	61.10	3.80	61.16	3.75				

*F/U=follow-up; DCO=diffuse of carbon monoxide; RV=residual volume; TLC=total lung capacity.

[†]Dyspnea score by Modified Medical Research Council (MMRC) Dyspnea Scale.

[‡]p<0.05 compared with patients with multiple follow-up visits.

pulmonary function tests (at least 30 days apart) within the first 6 months postoperatively. To be included in the long-term follow-up evaluation analyses, patients were required to have at least two follow-up pulmonary function analyses (at least 120 days apart) ≥ 6 months postoperatively.

The change in FEV₁ at the time of initial follow-up was determined for all patients whose initial follow-up visit was within 6 months of surgery (Table 3 and Figure 1). The maximal short-term postoperative improvement was defined as the highest FEV₁ measured within the 6 months postsurgery.

Long-term follow-up rate of change in FEV₁ was determined from the slope of linear regression of follow-up data in each patient with multiple measurements >6 months postsurgery. The mean of the individual regression slope and SEM are reported as the average decline in lung function long term (using only the data obtained ≥ 6 months postoperatively) reported on an annualized basis as liters per year.

Statistical Analysis

Differences between baseline characteristic among treatment groups were investigated using *t* tests (for comparisons between two groups) and analysis of variance (comparison of more than

two groups). The measure of clinical outcome used in the analyses was change in FEV₁. Descriptive statistics mean, SD, SE, median and ranges were performed for all quantitative variables. Linear regression was used to calculate change in lung function over the specified time intervals. Analyses were conducted using a statistical software package (Systat 6.0 for Windows; SPSS Inc; Chicago).

Rehabilitation

Patients did not receive preoperative rehabilitation at the Medical Center prior to LVRS. All patients underwent a similar regimen of pulmonary rehabilitation at Chapman Medical Center beginning immediately following hospital discharge surgery. The rehabilitation consists of a 10-day outpatient regimen involving a multidisciplinary approach with nursing, respiratory, dietary, nutritional, psychosocial, occupational, and physical therapy. Patient education, physical exercise (walking, flexibility, and strengthening), self-monitoring, breathing retraining, and bronchial hygiene instruction are included.

Table 2—Number of Patients with Follow-up Pulmonary Function Tests

	Patients Undergoing LVRS	LVRS Patients Without Follow-up	LVRS Patients With Single Follow-up	LVRS Patients With Multiple Follow-up Visits		
				Total	Short Term	Long Term
All patients	376	45	151	180	145	110
Unilateral thoracoscopic laser	46	7	5	34	24	18
Unilateral thoracoscopic staple	111	16	49	46	22	35
Bilateral thoracoscopic staple	184	15	79	90	90	49
Bilateral median sternotomy staple	14	4	7	3	3	3
Combined unilateral thoracoscopic staple and laser	21	3	11	7	6	5

Table 3—Change in FEV₁ Following LVRS*

	n	Preop FEV ₁ , L		Postop FEV ₁ , L		6-mo Postop FEV ₁ , L		Maximal Change in FEV ₁ at 6 mo, L		Slope of FEV ₁ Long Term (>6 mo L/yr)		Median Follow-up, d	
		Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Median	Range
All patients	180	0.66	0.013	0.87	0.02	0.94	0.02	0.28	0.01	-0.163	0.035	356	34-891
Unilateral thoracoscopic laser	34	0.64	0.04	0.7	0.04	0.74	0.04	0.1	0.03	-0.074	0.034	371	328-793
Unilateral thoracoscopic staple	46	0.71	0.03	0.86	0.03	0.86	0.01	0.25	0.03	-0.107	0.068	426	48-891
Bilateral thoracoscopic staple	90	0.69	0.02	1.08	0.03	1.13	0.05	0.39	0.03	-0.255	0.057	230	35-742
Bilateral median sternotomy staple	3	0.73	0.087	1.03	0.09	0.97	0.7	0.3	0.09	-0.081	0.187	297	34-538
Combined unilateral thoracoscopic staple and laser	7	0.64	0.07	0.78	0.06	0.86	0.15	0.22	0.1	-0.209	0.12	428	69-826

*Preop=preoperative; postop=postoperative.

RESULTS

Composite Results in All Patients

A total of 376 patients underwent LVRS in this program during the analysis interval: 46 patients underwent unilateral laser LVRS; 111 had unilateral thoracoscopic staple LVRS; 184 had bilateral thoracoscopic

staple LVRS; 21 had mixed thoracoscopic laser and staple procedures; and 14 had bilateral staple LVRS via median sternotomy. There were 15 perioperative deaths (mortality rate, 3.98%). In the overall group; follow-up pulmonary function results are available on 331 of the 361 surviving patients (92%) at some time following surgery (Tables 4 and 5).

FIGURE 1. Lung function (FEV₁) following LVRS procedures. Time in months is shown on the x-axis. Dotted lines show slopes of deterioration in FEV₁ from the 6-month average FEV₁ based on procedure. Error bars denote SEM.

Table 4—Mortality Following LVRS

	Total No. of Patients	Average Follow-up Days, Mean±SEM	Total No. Died	Expiration Days Postoperative
All patients	376	505±16	76	
Unilateral laser	46	507±46	8	30,60,190,210,270,640,840,870
Unilateral staple	111	591±32	31	5,6,10,11,30,30,42,44,50,51,51,60,63,135,139,156,194,210,210,220,240,309,365,395,485,503,540,690,750,760,970
Bilateral median sternotomy	184	430±15	5	10,70,183,600,660
Bilateral staple	14	479±55	26	3,3,5,10,14,20,25,30,30,37,38,49,51,66,90,165,182,270,284,365,380,405,510,580,640,745
Combined laser and staple	21	560±21	6	6,80,128,250,360,780

Baseline FEV₁ for all patients in this study was 0.66 L±0.013 L (SEM). Mean improvement in FEV₁ for all patients was 0.28 L±0.02 L SEM (42%±3% SEM change from baseline) at the time of 6-month follow-up.

One hundred eighty of the patients had multiple follow-up visits (short and long term) following surgery enabling them to be analyzed for the rate of postoperative FEV₁ over time following surgery. Those with multiple follow-up had similar preoperative presentations and similar postoperative results as those with single follow-up visit data, with a mean baseline FEV₁ of 0.67 L±0.014 L (SEM), and improvement in FEV₁ of 0.28 L±0.016 L (SEM) (42%±3% change from baseline at the time of 6-month follow-up).

One hundred forty-five patients had multiple follow-up pulmonary function analyses within the first 6 months following surgery. FEV₁ increased from 0.67±0.01 L (SEM) to 0.87±0.02 L (SEM) at the time of initial follow-up after surgery (mean, 38 days postoperatively). On average, pulmonary function continued to improve during this early postoperative

period with a mean additional increase in FEV₁ of 0.067±0.027 L (SEM) (*ie*, a further 10%±4% increase from baseline) during an average follow-up interval 99.6±37 days postoperatively. Overall, the mean change in FEV₁ from preoperative to the maximal value reached within 6 months postoperatively was 0.28 L (31%±7% change from baseline).

One hundred ten patients had multiple long-term follow-up pulmonary function analyses from 6 months following surgery to as long as 891 days postoperatively (mean follow-up time, 505±16 days [SEM]). After the initial 6-month rise, pulmonary function showed a general decline with a mean slope in FEV₁ of -0.163±0.035 (SEM) L/yr.

Unilateral Thoracoscopic Laser LVRS-Treated Patients

Mean improvement in FEV₁ was 0.10 L±0.03 L (15%±9% [SEM] change from baseline FEV₁ of 0.64±0.04 L) at the time of initial follow-up in 34 unilateral laser-treated patients, which was significantly lower than the improvement seen in unilateral or bilateral staple-treated patients (*p*<0.05).

In long-term follow-up after 6 months postoperatively, unilateral thoracoscopic laser-treated patients had an average decline in FEV₁ of 0.074±0.034 L/yr (average follow-up, 507±46 days).

Unilateral Thoracoscopic Staple LVRS-Treated Patients

Mean improvement in FEV₁ was 0.15±0.02 L (SEM) (21%±3% change from baseline FEV₁ of 0.71±0.03 L) [SEM] at the time of initial follow-up in 90 unilateral staple-treated patients. The 22 staple-treated patients with multiple short-term follow-up visits showed further improvement in FEV₁ in the initial 6 months following surgery, with a rise of 0.10 L to a maximal value reached of 0.96±0.1 L (SEM) (35%±14% [SEM] change from baseline).

In long-term follow-up after 6 months postoperatively, unilateral thoracoscopic staple-treated pa-

Table 5—Causes of Death in LVRS-Treated Patients

Cause of Death	No. Patients
Amyotrophic lateral sclerosis	1
Aortic aneurysm	1
Bacterial colitis	1
Cancer	1
Cardiac arrest	7
Cardiovascular collapse	1
GI bleed	1
Ischemic bowel	1
Myocardial infarction	1
Pulmonary emboli	3
Respiratory failure	49
Stroke	2
Suicide	1
Trauma	1
Unknown	5
Total	76

tients had an average decline in FEV₁ of 0.107±0.068 L/yr (mean follow-up, 591±32 days).

Bilateral Thoracoscopic Staple LVRS-Treated Patients

Mean improvement in FEV₁ was 0.39±0.03 L (SEM) (56%±4% [SEM] change from baseline FEV₁ of 0.69±0.02 L [SEM]) at the time of initial follow-up in 170 thoracoscopic staple-treated patients. The 90 bilateral staple-treated patients with multiple follow-up visits showed progressive improvement in FEV₁ in the initial 6 months following surgery, with a further rise to the maximal value reached, 1.13±0.05 L (SEM) (60%±6% [SEM] change from baseline).

In long-term follow-up after 6 months postoperatively, bilateral thoracoscopic staple-treated patients had an average decline in FEV₁ of 0.255±0.057 L/yr (mean follow-up, 420±15 days).

Median Sternotomy Bilateral LVRS Patients

Mean improvement in FEV₁ was 0.30±0.09 L (SEM) (41%±13% change from baseline FEV₁ of 0.73±0.087 L [SEM]) at the time of initial follow-up in nine median sternotomy bilateral staple LVRS-treated patients. Maximum FEV₁ reached within 6 months by the five patients with median sternotomy with multiple follow-up was 0.97±0.7 L.

Only three patients with median sternotomies had repeated follow-up data available >6 months postoperatively to allow calculation of long-term rate of deterioration in FEV₁. In long-term follow-up after 6 months postoperatively, bilateral median sternotomy-treated patients had an average decline in FEV₁ of 0.081±0.187 L/yr (mean follow-up, 479±55 days) in these three patients.

Combined Bilateral Thoracoscopic Staple- and Laser-Treated LVRS Patients

Mean improvement in FEV₁ was 0.14±0.07 L (SEM) (22%±10% [SEM] change from baseline) at the time of initial follow-up in 18 unilateral combined staple- and laser-treated patients. The 10 combined staple- and laser-treated patients with multiple follow-up visits also showed continued improvement in FEV₁ in the initial 6 months following surgery, with a rise to the maximal value reached of 0.86±0.15 L (SEM) (28±7% [SEM] change from baseline).

Only seven patients with combined staple and laser thoracoscopic LVRS procedures had repeated follow-up data available. In long-term follow-up after 6 months postoperatively, these seven patients experienced an average decline in FEV₁ of 0.209±0.118 L/yr (mean follow-up, 560±72 days).

Correlation Between Initial Response to LVRS and Long-Term Rate of Decline in FEV₁

A weak correlation was found between the short-term incremental gain in FEV₁ postoperatively and the long-term rate in decline in FEV₁. Overall, patients with the greatest increase in FEV₁ had a greater long-term decline in FEV₁ after 6 months, though there was considerable individual variability in the relationship ($r=0.292$, $p=0.003$), and individual response could not be predicted.

When examined by individual procedure, this relationship between magnitude of short-term response and rate of deterioration was less evident, but trends persisted: for unilateral staple-treated patients, $r=0.417$, $p=0.12$; for unilateral laser-treated patients, $r=0.95$, $p=0.05$; for patients undergoing bilateral staple procedure, this relationship was not seen ($r=0.162$, $p=0.29$).

When the subgroup of bilateral staple-treated patients who had a small incremental benefit from LVRS was examined (improvement in FEV₁ <0.200 L), the rate of deterioration was 50 mL/yr lower than for patients with larger short-term FEV₁ improvement (improvement in FEV₁ >0.250 L).

DISCUSSION

LVRS has been shown to be acutely effective in providing palliative improvement in pulmonary function in patients with heterogeneous emphysema in a number of studies.^{1-6,9,12-17} Postoperative pulmonary function appears to maximize at approximately 3 to 6 months following surgery. Limited available data suggest that benefit may be sustained for at least 1 to 2 years following surgery in most patients.^{4,17} However, there is widely variable response to surgery as well as duration of improvement. Measurable physiologic deterioration has been seen by 1 year in some patients.¹⁸ It is very difficult to assess the rate of regression of pulmonary function in many series since consistent patient follow-up at regular, repeated intervals is extremely difficult to achieve long term at many centers.

We evaluated the rate of pulmonary function decline long term following LVRS by comparing the slopes of change in FEV₁ long term following LVRS using linear regression of lung function vs time. Individual regression lines were determined for FEV₁ from 0 to 6 months following surgery. A second regression line was determined for each patient 6 months postoperatively and beyond. In this manner, variability in the time of follow-up visits was taken into account. Using this method, a rate of decline for each individual patient was determined. This reduced errors that occur from having different

patient groups followed up at different time points. This also reduced errors in calculated deterioration rates due to samples containing different patients at each follow-up time or by reducing the total number of patients to cohorts with relatively small numbers who were followed up at all time points.

Using this method, we found that, on average, pulmonary function improved in the early postoperative period, and in most patients it appeared to peak between 3 and 6 months following surgery. These findings are consistent with our clinical experience and unpublished reports from other centers (A.F.W., R.Y.). The incremental improvements occurring in the first 6 months were variable and dependent to some degree on the procedure performed in patients in this series. The immediate and 6-month postoperative improvement was greatest for patients who underwent bilateral staple lung volume reduction procedures, and is reasonably comparable to other bilateral staple LVRS published series.^{1,3,4,6}

When examined as a composite group, lung function deteriorated long term (>6 months postoperatively). When long-term data were averaged, the rate of decline in FEV₁ was 163 mL/yr. Since the average incremental gain from the preoperative values to the 6-month maximum value was 280 mL, one could predict from this rate of decline that the average patient should return toward preoperative baseline levels by about 2 years postoperatively. However, validity of such a prediction is limited by a number of factors. First, the rate of decline appears to be related to the operative procedure and to the short-term incremental benefit following surgery. The conditions of those patients with the greatest incremental gains in lung function following surgery appeared to deteriorate more rapidly than those with smaller postoperative gains. Individual variability was extremely high and predictions cannot be applied to an individual patient. Additionally, some patients had relatively short intervals between follow-up visits. When such patients had significant changes in their lung function between visits, a very large slope was obtained. When these large slopes are averaged with the slopes of patients with much longer follow up, they receive disproportionate weight in calculating the rate of change in lung function. In other words, averaging the slopes does not equitably "weight adjust" for the total follow-up duration for individual patients.

As previously reported,^{2,3,6} we found that bilateral stapled LVRS appears to provide the greatest short-term benefits in terms of improvement in FEV₁. However, bilateral stapled lung volume reduction procedures also were associated with the greatest rate of decline in lung function long term. While such a finding may be expected, it again raises

questions as to whether sequential unilateral procedures could be potentially more beneficial over a very long period of time. Obviously we cannot answer this question from the current study.

In this series, bilateral staple LVRS patients showed deterioration of FEV₁ at an average annualized rate of 0.255 L/yr long term. Cooper et al¹¹ reported a drop in FEV₁ of 0.1 L in a cohort of 56 patients from the time of 6-month follow-up until 12-month follow-up. This could represent up to 0.2-L annualized decrease, though longer-term data are needed.¹¹ If the patient cohort of Cooper et al¹¹ experienced a slower rate of decline than that found in our patients long term, careful analysis of possible reasons for the differences would be warranted.

Unilateral laser LVRS procedures resulted in very small benefits in patients in our series. However, they had a correspondingly lower rate of deterioration of lung function. There were too few patients in this study who had serial long-term follow-up after median sternotomy LVRS procedures or combined laser and staple LVRS to draw any conclusions regarding their relative rates of decline in lung function long term.

There are a number of important limitations of this study. The long-term rate of deterioration in lung function was calculated using linear regression of the FEV₁ over time for each patient. It is possible that the change in FEV₁ postoperatively is not linear after 6 months. If the rate of decline in FEV₁ is greatest around 6 months, and slows later (as might be expected from stress relaxation), the rate of decline would appear greater for the bilateral procedures, since these patients have been followed up for the shortest average time. This might explain some of the steeper FEV₁ deterioration slopes seen in the bilateral staple-treated patients. Nonlinear regression analyses could be considered when more data are available on larger numbers of patients in the future. We examined FEV₁ as the only measure of pulmonary function outcome. Clearly, other pulmonary function variables could lead to different conclusions. We selected FEV₁ since it is objective, widely reported, reproducible, and obtained spirometrically. However, FEV₁ has well-described limitations as an isolated end point for measurement of emphysema and response to surgery. Additionally, we evaluated FEV₁ response in absolute numbers (liters) to arrive at a deterioration rate in liters per year. This does not account for differences in age, size, predicted FEV₁, or percent change from baseline.

The selection criteria for patients in the various procedures differed to some degree, as did the experience of the surgeons at the time of enrollment

for some of the patient groups. This could affect duration of response and rate of deterioration of lung function.

A substantial percentage of patients in each group did not have multiple long-term follow-up visits necessary to include them in rate of change of FEV₁ analyses. Bias may have occurred based on resulting follow-up selection. Finally, interpretation of the long-term value of these procedures is complicated since the natural rate of decline in a comparably matched control group of patients is also difficult to determine.

In summary, we have found that lung function appears to improve in the first few months following LVRS and appears to maximize at approximately 3 to 6 months following surgery in most patients. The short-term incremental improvement following bilateral staple procedures is superior to improvements following other procedures or unilateral surgery. However, the more rapid rate of decline in patients with bilateral staple lung volume reduction procedures (and the general association between greater incremental improvement and higher rate of the deterioration) raises questions regarding optimal long-term procedures. Further studies will clearly be needed to answer these important questions.

REFERENCES

- 1 Yusen R, Trulock E, Horowitz M, et al. Physiologic profile of patients with emphysema before and after lung volume reduction surgery [abstract]. *Am J Respir Crit Care Med* 1995; 151:A12
- 2 McKenna RJ, Brenner M, Gelb AF, et al. Should lung volume reduction surgery be unilateral or bilateral? *J Thorac Cardiovasc Surg* 1996; 112:1331-39
- 3 Cooper JD, Patterson GA. Lung volume reduction surgery for severe emphysema. *Semin Thorac Cardiovasc Surg* 1996; 8:52-60
- 4 Cooper JD, Lefrak SS. Is volume reduction surgery appropriate in the treatment of emphysema? yes [editorial]. *Am J Respir Crit Care Med* 1996; 153(pt 1):1201-04
- 5 McKenna RJ, Brenner M, Gelb AF, et al. A randomized, prospective trial of stapled lung reduction versus laser bullectomy for diffuse emphysema. *J Thorac Cardiovasc Surg* 1996; 111:317-21
- 6 Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. *J Thorac Cardiovasc Surg* 1995; 109: 106-16
- 7 Wakabayashi A, Brenner M, Kayaleh RA, et al. Thoracoscopic carbon dioxide laser treatment of bullous emphysema. *Lancet* 1991; 337:881-83
- 8 Wakabayashi A. Thoracoscopic laser pneumoplasty in the treatment of diffuse bullous emphysema. *Ann Thorac Surg* 1995; 60:936-42
- 9 Little AG, Swain JA, Nino JJ, et al. Reduction pneumoplasty for emphysema: early results. *Ann Surg* 1995; 222:365-71
- 10 Eugene J, Ott RA, Gogia HS, et al. Video-thoracic surgery for treatment of end-stage bullous emphysema and chronic obstructive pulmonary disease. *Am Surg* 1995; 61:934-36
- 11 Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. *J Thorac Cardiovasc Surg* 1996; 112:1319-29
- 12 Deloney P, Pohl M, Biggar D, et al. Functional results before and after pulmonary rehabilitation and following bilateral lung volume reduction surgery in patients with COPD [abstract]. *Am J Respir Crit Care Med* 1995; 151:A12
- 13 Pohl M, Deloney P, Biggar D, et al. Dyspnea and quality of life for patients pre- and post-volume reduction surgery [abstract]. *Am J Respir Crit Care Med* 1995; 151:A13
- 14 Little AG. Lung volume reduction: a breath of fresh air? *Chest* 1996; 110:2-3
- 15 Naunheim KS, Ferguson MK. The current status of lung volume reduction operations for emphysema. *Ann Thorac Surg* 1996; 62:601-12
- 16 Yusen RD, Trulock EP, Pohl MS, et al. Results of lung volume reduction surgery in patients with emphysema: the Washington University Emphysema Surgery Group. *Semin Thorac Cardiovasc Surg* 1996; 8:99-109
- 17 Roue C, Mal H, Sleiman C, et al. Lung volume reduction in patients with severe diffuse emphysema: a retrospective study. *Chest* 1996; 110:28-34
- 18 Gelb AF, Brenner M, McKenna RJ, et al. Lung function 12 months following emphysema resection. *Chest* 1996; 110: 1407-15